Clinical Trial

Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM

LOS ANGELES, Aug. 6, 2024 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi) announces a $1M investment commitment by the Myeloma Investment…

1 year ago

Lindus Health Unveils “All-in-One Dermatology CRO” Offering for Dermatology Clinical Trials

NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life…

1 year ago

Jennifer Stacey Joins PicnicHealth as Chief Delivery Officer

SAN FRANCISCO, Aug. 6, 2024 /PRNewswire/ -- Today, PicnicHealth, a company dedicated to simplifying observational research, announced the appointment of Jennifer…

1 year ago

Luminopia Covered by Highmark Health for Treatment of Pediatric Amblyopia

Luminopia meets rigorous criteria set by Highmark's New Technology Advisory Committee (NTAC) and receives a positive coverage determination from the…

1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…

1 year ago

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter…

1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage…

1 year ago

NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company…

1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year…

1 year ago

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose…

1 year ago